Original Article

Two Enhances the Cisplatin Sensitivity of Cervical Cancer Cells via Suppression of c-MET Expression

Abstract

Background: The drug resistance of chemotherapeutic agents leads to unsatisfactory survival rates for cervical cancer (CC) patients. We aimed to explore the effect of FOXP2 on the sensitivity of CC cells to cisplatin (DDP) and its mechanism in Changde, China in 2018.

Methods: A Total of 6 cervical cancer tissue samples including 3 patients with cisplatin sensitivity and 3 patients with cisplatin resistance, who received DDP-based treatment, were obtained from Changde First People's Hospital, Changde City during 2021，and FOXP2 level was detected by Western blot. The expression levels of FOXP2 and c-MET (hepatocyte growth factor receptor, c-MET) in cells were determined by q-PCR and Western blot analysis. The cell survival, apoptosis, and clone formation were analyzed by flow cytometry, MTT assay, or clone formation assay. Dual-luciferase reporter assays and Chromatin immunoprecipitation were applied to verify the regulation between FOXP2 and c-MET.

Results: FOXP2 was downregulated in cisplatin-resistant cervical cancer tissues and cells compared with control. FOXP2 overexpression in SiHa/DDP cells inhibited cell proliferation and promoted cell apoptosis, whereas down-regulation of FOXP2 in SiHa cells had the opposite result. FOXP2 enhanced chemosensitive to DDP in CC cells. FOXP2 is negatively correlated with c-MET expression level in SiHa and SiHa/DDP cells. Mechanistically, FOXP2 binds to the promoter region of c-MET to regulate its expression in CC cells negatively. Overexpression of c-MET can attenuate the enhancement of DDP-induced apoptosis caused by FOXP2 overexpression.

Conclusion: This is a novel study on the role of FOXP2 in promoting the DDP sensitivity of CC cells by inhibiting c-MET. The FOXP2/c-MET signaling axis uncovered in the present study may be a novel therapeutic target for the DDP therapy resistance of CC.

1. Sung H, Ferlay J, Siegel R L, et al (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 71 (3): 209-249.
2. Pry J M, Manasyan A, Kapambwe S, et al (2021). Cervical cancer screening outcomes in Zambia, 2010-19: a cohort study. Lancet Glob Health, 9 (6): e832-e840.
3. Liu Y, Guo R, Qiao Y, et al (2020). LncRNA NNT-AS1 contributes to the cisplatin resistance of cervical cancer through NNT-AS1/miR-186/HMGB1 axis. Cancer Cell Int, 20:190.
4. Co M, Anderson A G, Konopka G (2020). FOXP transcription factors in vertebrate brain development, function, and disorders. Wiley Interdiscip Rev Dev Biol, 9 (5): e375.
5. Hunter P (2019). The riddle of speech: After FOXP2 dominated research on the origins of speech, other candidate genes have recently emerged. EMBO Rep, 20 (2):e47618
6. Kim J H, Hwang J, Jung J H, et al (2019). Molecular networks of FOXP family: dual biologic functions, interplay with other molecules and clinical implications in cancer progression. Mol Cancer, 18 (1): 180.
7. Liu Y, Chen T, Guo M, et al (2021). FOXA2-Interacting FOXP2 Prevents Epithelial-Mesenchymal Transition of Breast Cancer Cells by Stimulating E-Cadherin and PHF2 Transcription. Front Oncol, 11: 605025.
8. Li Y, Wang H, Huang H (2019). Long non-coding RNA MIR205HG function as a ceRNA to accelerate tumor growth and progression via sponging miR-122-5p in cervical cancer. Biochem Biophys Res Commun, 514 (1): 78-85.
9. Gascoyne D M, Spearman H, Lyne L, et al (2015). The Forkhead Transcription Factor FOXP2 Is Required for Regulation of p21WAF1/CIP1 in 143B Osteosarcoma Cell Growth Arrest. PLoS One, 10 (6): e0128513.
10. Wang H, Deng Z, Chen X, et al (2019). Downregulation of miR-222-3p Reverses Doxorubicin-Resistance in LoVo Cells Through Upregulating Forkhead Box Protein P2 (FOXP2) Protein. Med Sci Monit, 25: 2169-2178.
11. Comoglio P M, Trusolino L, and Boccaccio C (2018). Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy. Nat Rev Cancer, 18 (6): 341-358.
12. Guo R, Luo J, Chang J, et al (2020). MET-dependent solid tumours - molecular diagnosis and targeted therapy. Nat Rev Clin Oncol, 17(9): 569-587.
13. Sanchez-Vega F, Hechtman J F, Castel P, et al (2019). and Amplifications Determine Response to HER2 Inhibition in -Amplified Esophagogastric Cancer. Cancer Discovery, 9 (2): 199-209.
14. Refaat T, Donnelly E D, Sachdev S, et al (2017). c-Met Overexpression in Cervical Cancer, a Prognostic Factor and a Potential Molecular Therapeutic Target. Am J Clin Oncol, 40(6): 590-597.
15. Zhai Y, Wu W, Xi X, Yu R (2020). Adipose-Derived Stem Cells Promote Proliferation and Invasion in Cervical Cancer by Targeting the HGF/c-MET Pathway. Cancer Manag Res, 12 11823-11832.
16. Oh HN, Kwak AW, Lee MH, et al (2021). Targeted inhibition of c-MET by podophyllotoxin promotes caspase-dependent apoptosis and suppresses cell growth in gefitinib-resistant non-small cell lung cancer cells. Phytomedicine, 80:153355.
17. Zhang Q, Zhang H, Ning T, et al (2020). Exosome-Delivered c-Met siRNA Could Reverse Chemoresistance to Cisplatin in Gastric Cancer. Int J Nanomedicine, 15: 2323-2335.
18. Mukamel Z, Konopka G, Wexler E, et al (2011). Regulation of MET by FOXP2, genes implicated in higher cognitive dysfunction and autism risk. J Neurosci, 31(32): 11437-11442.
19. Jing L, Bo W, Yourong F, et al (2019). Sema4C mediates EMT inducing chemotherapeutic resistance of miR-31-3p in cervical cancer cells. Sci Rep, 9(1): 17727.
20. Hou Z, Guo K, Sun X, et al (2018). TRIB2 functions as novel oncogene in colorectal cancer by blocking cellular senescence through AP4/p21 signaling. Mol Cancer, 17(1): 172.
21. Wang J, Pollard K, Calizo A, Pratilas CA (2021). Activation of Receptor Tyrosine Kinases Mediates Acquired Resistance to MEK Inhibition in Malignant Peripheral Nerve Sheath Tumors. Cancer Res, 81(3): 747-762.
22. Dasari S, Tchounwou PB (2014). Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol, 740: 364-78.
23. Masadah R, Rauf S, Pratama M Y, et al (2021). The Role of microRNAs in the Cisplatin- and Radio-Resistance of Cervical Cancer. Cancers (Basel), 13 (5):1168
24. Bhatla N, Aoki D, Sharma D N, Sankaranarayanan R (2018). Cancer of the cervix uteri. Int J Gynaecol Obstet, 143 Suppl 2: 22-36.
25. Spina A, De Pasquale V, Cerulo G, et al (2015). HGF/c-MET Axis in Tumor Microenvironment and Metastasis Formation. Biomedicines, 3 (1): 71-88.
26. Bradley C A, Salto-Tellez M, Laurent-Puig P, et al (2018). Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges. Nat Rev Clin Oncol, 15(3):150.
27. Nishiguchi Y, Oue N, Fujiwara-Tani R, et al (2019). Role of Metastasis-Related Genes in Cisplatin Chemoresistance in Gastric Cancer. Int J Mol Sci, 21 (1):254.
28. Tang XL, Yan L, Zhu L, et al (2017). Salvianolic acid A reverses cisplatin resistance in lung cancer A549 cells by targeting c-met and attenuating Akt/mTOR pathway. J Pharmacol Sci, 135(1): 1-7.
29. Sun CY, Zhu Y, Li XF, et al (2018). Scutellarin Increases Cisplatin-Induced Apoptosis and Autophagy to Overcome Cisplatin Resistance in Non-small Cell Lung Cancer via ERK/p53 and c-met/AKT Signaling Pathways. Front Pharmacol, 9: 92.
30. Joosten S P J, Mizutani T, Spaargaren M, et al (2019). MET Signaling Overcomes Epidermal Growth Factor Receptor Inhibition in Normal and Colorectal Cancer Stem Cells Causing Drug Resistance. Gastroenterology, 157(4):1153-1155.
31. Kina S, Phonaphonh T, Liang F, et al (2013). PDGF α receptor is a mediator for Cisplatin-induced Met expression. Eur J Pharmacol, 699 (1-3): 227-232.
Files
IssueVol 52 No 7 (2023) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijph.v52i7.13249
Keywords
Cervical cancer Cisplatin (DDP) Chemoresistance
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Chen Z, Xiao Z, Tian W, Li Z, Wu T. Two Enhances the Cisplatin Sensitivity of Cervical Cancer Cells via Suppression of c-MET Expression. Iran J Public Health. 2023;52(7):1476-1486.